Bharat Biotech's COVID-19 shot has 78% efficacy in clinical trials, according to new study
Bharat Biotech's COVID-19 shot has 78% efficacy in clinical trials, according to new study
Bharat Biotech Ltd.'s COVID-19 vaccine has an overall efficacy rate of 77.8% when it comes to preventing symptomatic disease, according to a new study published Thursday in The Lancet. The findings are from a Phase 3 clinical trial conducted in India that had more than 25,000 adult participants; they are in line with the company's previous statements about the vaccine's efficacy rate. The research also found that Covaxin has an efficacy rate of 93.4% at preventing severe disease. The privately held company, which jointly developed the vaccine with the Indian Council of Medical Research, has said Covaxin has been administered to more than 100 million adults worldwide. It is not authorized in the U.S. Ocugen Inc. (OCGN), which has commercialization rights to the vaccine in the U.S., said last week that it has asked the Food and Drug Administration to authorize Covaxin in children between the ages of 2 and 18 years old.
根据周四发表在“柳叶刀”上的一项新研究，巴拉特生物技术有限公司(Bharat Biotech Ltd.)的新冠肺炎疫苗在预防症状性疾病方面的总有效率为77.8%。这一发现来自于在印度进行的一项3期临床试验，该试验有超过2.5万名成年人参与；这与该公司之前关于疫苗有效率的声明是一致的。研究还发现，Covaxin在预防严重疾病方面的有效率为93.4%。这家私人持股公司与印度医学研究理事会(Indian Council Of Medical Research)联合开发了这种疫苗，该公司表示，Covaxin已经在全球超过1亿成年人身上接种。在美国拥有疫苗商业化权利的美国Ocugen Inc.(OCGN)上周表示，它已要求美国食品和药物管理局(Food And Drug Administration)授权Covaxin在2岁至18岁的儿童中使用。Ocugen Inc.(OCGN)在美国拥有该疫苗的商业化权利，该公司未获授权。
-Jaimy Lee
--杰米·李(Jaimy Lee)